Skip to main content

Aptose Biosciences Inc(APS-T)
TSX

Today's Change
Real-Time Last Update
Day Low2.00
Day High2.12
Open:2.12
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
GlobeNewswire
Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024
GlobeNewswire
Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option
GlobeNewswire
Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical
GlobeNewswire
Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting
GlobeNewswire
Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role
GlobeNewswire
Aptose Reports Results for the Third Quarter 2023
GlobeNewswire
Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting
GlobeNewswire
Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib
GlobeNewswire
Aptose to Report Third Quarter 2023 Financial Results and Hold Conference Call on Thursday, November 9, 2023
Baystreet
Stocks in play: Aptose Biosciences Inc.
GlobeNewswire
Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th
Baystreet
Stocks in play: Aptose Biosciences Inc.
GlobeNewswire
Aptose Clinical and Preclinical Data to be Presented at European School of Haematology (ESH) 6th International Conference
GlobeNewswire
Aptose to Present at the Cantor Global Healthcare Conference
GlobeNewswire
Aptose Announces Closing of $3 Million Investment by Hanmi Pharmaceutical
Baystreet
Stocks in play: Aptose Biosciences Inc.
GlobeNewswire
Aptose to Present at the H.C. Wainwright 25th Annual Global Investment Conference
GlobeNewswire
Aptose Reports Results for the Second Quarter 2023

Profile

Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.